Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: early in vivo cardiovascular effects

Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: early in vivo cardiovascular effects / Gavazzoni, M., Lombardi, C., Vizzardi, E., Gorga, E., Sciatti, E., Rossi, L., Belotti, A., Rossi, G., Metra, M., Raddino, R.. - In: EUROPEAN JOURNAL OF PHARMACOLOGY. - ISSN 0014-2999. - (2018).